AzTrials
AzTrials

Ulcerative ColitisPhase 3NCT02039505

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

A Phase 3 study testing Vedolizumab in people with Ulcerative Colitis, run by Takeda at 59 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC). Read more about this study

Who is it for?
Ages 15 to 80 years
Conditions the study is for
Ulcerative Colitis
What is being tested?
Vedolizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
292 participants
Where
59 sitesJapan
Study dates
4 Feb 2014to 28 Jun 2018
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 80 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • In the opinion of the investigator, a participant is capable of understanding and complying with protocol requirements.
  • A participant who is capable of entering the signature and the date on the informed consent by himself/herself or by the participant's legally acceptable representative, if applicable, prior to initiation of study procedures.
  • A participant aged 15 to 80 (inclusive) at the time of signing the informed consent (regardless of sexes).
  • A male participant, who has no sterilization history and whose female partner has child-bearing potential, who agreed with taking proper contraception during the period from the time of signing the informed consent form through 6 months after the last dose of study drug.
  • A female participant with child-bearing potential (having no history of sterilization or whose last menstruation was within 2 years) whose male partner is not receiving contraceptive treatment, and agreed to take proper contraception during the period from the time of signing on the informed consent form through 6 months after the last dose of the study drug.
  • Participants with diagnosis of total or left-sided ulcerative colitis (UC) based on the Revised Diagnostic Criteria for UC issued by "Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease" by the Ministry of Health, Labor and Welfare (MHLW) of Japan (2012) at least 6 months before the start of administration of the study drug.
Show all 20Show fewer
  • A participant with moderately or severely active UC as determined by baseline complete Mayo score of 6 to 12 (inclusive) with an endoscopic subscore of ≥2.
  • Participants whose complication of colon cancer or dysplasia had to be ruled out by total colonoscopy at the start of the study drug administration (or the results from total colonoscopy performed within 1 year before giving consent are available), if participants met any of the following criteria; participants with ≥8-year history of total or left-sided colitis, participants aged ≥50 years, or participants with a first-degree family history of colon cancer.
  • Participants meeting the following treatment failure criteria with at least one of the following agents within 5 years before signing on the informed consent:
  • Corticosteroids
  • Resistance: Participants whose response was inadequate after treatment of ≥40 mg/day for ≥1 week (oral or IV) or 30 to 40 mg/day for ≥2 weeks (oral or IV).
  • Dependence: Participants for which it is difficult to reduce the dosage to <10 mg/day due to recurrence during gradual dose reduction (oral or IV).
  • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., Cushing's syndrome, osteopenia/osteoporosis, hyperglycaemia, insomnia, infection).
  • Immunomodulators (azathioprine [AZA] or 6- mercaptopurine [6-MP])
  • Refractory: Participants whose response was inadequate after treatment for ≥12 weeks.
  • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase genetic mutation, infection).
  • Tumor necrosis factor-alpha (TNFα) antagonist
  • Inadequate response: Participants whose response was inadequate after the induction therapy in the dosage described in the package insert.
  • Loss of response: Participants who had recurrence during the scheduled maintenance therapy after achievement of clinical response (those who withdrew for other reasons than relapse are not applicable here).
  • Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (eg, infusion-related reaction, demyelination, congestive heart failure, infection).

Who cannot join

  • Participants whose partial Mayo score decrease by 3 points or more between screening and the start of study drug administration.
  • Participants having or suspected to have abdominal abscess or toxic megacolon.
  • Participants with a history of subtotal or total colectomy.
  • Participants with ileostomy, colostomy, fistula or severe intestinal stenosis.
  • Participants having a treatment history with natalizumab, efalizumab or rituximab.
  • Participants who started oral 5-ASA, probiotics, or oral corticosteroids (≤30 mg/day) within 13 days before the first dose of the study drug. Participants who have used these drugs for at least 14 days before the first dose of the study drug, and who changed dosage of or discontinued these drugs within 13 days before the first dose of the study drug.
Show all 44Show fewer
  • Participants who have received 5-ASA, corticosteroid enemas/suppositories, corticosteroid IV infusion, oral corticosteroid at >30 mg/day, drugs for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the UC treatment (eg, Daikenchuto) within 13 days before the first dose of the study drug.
  • Participants who have used an antidiarrheal drug for 4 or more consecutive days within 13 days before the first dose of the study drug or within 7 days before the first dose of the study drug.
  • Participants who have received AZA or 6-MP within 27 days before the first dose of the study drug However, this will not apply to participants who have used these drugs for 83 or more days before the first dose of the study drug and continued the steady dose administration of the drugs for 27 or more days before the first dose of the study drug.
  • Participants who have received cyclosporine, tacrolimus, methotrexate, tofacitinib or any study drugs of low-molecular compound for UC treatment within 27 days before the first dose of the study drug.
  • Participants who have received adalimumab within 27 days before the first dose of the study drug or any biologic agents other than adalimumab within 55 days before the first dose of the study drug. However, this will not apply to participants who have topically received these drugs (eg., intraocular injection for treatment of age-related macular degeneration).
  • Participants who have received any live-vaccinations within 27 days before the first dose of the study drug.
  • Participants who underwent the enterectomy within 27 days before the first dose of the study drug or those anticipated to require an enterectomy during the study.
  • Participants who have received leukocytapheresis or granulocyte apheresis within 27 days before the first dose of the study drug.
  • Participants who have been infected with an intestinal pathogen including clostridium difficile or cytomegalovirus within 27 days before the first dose of the study drug.
  • Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration.
  • Participants with a history or a complication of colonic mucosal dysplasia.
  • Participants suspected to have enteritis other than UC.
  • Participants indicated in the screening test as hepatitis B surface (HBs) antigen-positive or hepatitis C virus (HCV) antibody-positive. Participants indicated as hepatitis B core (HBc) antibody-positive or HBs antibody positive even though HBs antigen-negative However, the criteria will not apply to those with only HBs antibody-positive due to hepatitis B virus (HBV) vaccination, HBV-DNA-negative, HCV antigen-negative or HCV-RNA-negative.
  • Participants who have or are suspected to have a history of tuberculosis (including those whose findings in the chest imaging procedure at screening showing anamnesis of tuberculosis). However, the criteria will not apply to those who had completed prophylactic treatment with isoniazid, and who have been receiving prophylactic isoniazid for 21 days or longer before the first dose of the study drug (the latter may initiate study drug administration with screening phase extended to 28 days at maximum for prophylactic treatment to become 21 days or more).
  • Participants indicated as positive in T-SPOT or QuantiFERON at screening test.
  • Participants who have a history or complication of identified congenital or acquired immunodeficiency syndrome (eg, not-classifiable immunodeficiency, human immunodeficiency virus [HIV] infection or organ transplantation).
  • Participants who were affected by extra-intestinal infection (eg, pneumonia, sepsis, active hepatitis or pyelonephritis) within 27 days before the first dose of the study drug.
  • Participants who have treatment history with MLN0002.
  • Nursing mothers during the screening phase, or female participants indicated positive in urine pregnancy test either at the screening or baseline.
  • Participants having serious complications in the heart, lung, liver, kidney, metabolism, gastrointestinal system, urinary system, endocrine system or blood.
  • Participants with a history of an operation requiring general anesthesia within 27 days before the first dose of the study drug, or with a schedule of an operation requiring hospitalization during the study period.
  • Participants having a complication or a history of malignancy However, it will not apply to the following participants;
  • Participants who had a curative resection of localized skin basal cell carcinoma or had completed curative radiotherapy.
  • Participants who have not experienced recurrence for 1 year or longer since completion of curative resection or curative radiotherapy for skin squamous cell carcinoma.
  • Participants who have not experienced recurrence for 3 year or longer since completion of curative resection or curative radiotherapy for intraepithelial carcinoma of uterine cervix.
  • For participants having a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the Investigator and the sponsor will discuss to decide eligibility on the basis of type of malignancy and treatment applied.
  • Participants having a history or a complication of the central nervous disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  • Participants for which any subjective symptoms in the Subjective PML checklist were found at the screening or baseline.
  • Participants for which any of the following laboratory abnormalities were found at the screening;
  • Hemoglobin ≤8 g/dL
  • White blood cells ≤3,000/μL
  • Lymphocytes ≤500/μL
  • Platelets ≤100,000/μL, or ≥1,200,000/μL
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×upper limit of normal (ULN)
  • Alkaline phosphatase (ALP) ≥3×ULN
  • Creatinine ≥2×ULN
  • Participants having a history or a complication of alcohol dependence or illicit drug use within one year before the first dose of the study drug.
  • Participants having a history or a complication of psychotic disorder that may obstruct compliance with the study procedures.

Trial locations and contacts

59 sites in 1 country.

59 sites in 1 country

Japan59 sites

  • Study site

    Adachi-ku, Tokyo

  • Study site

    Akashi-shi, Hyōgo

  • Study site

    Asahikawa-shi, Hokkaido

  • Study site

    Beppu-shi, Ohita

  • Study site

    Bunkyo-ku, Tokyo

  • Study site

    Chikushino-shi, Fukuoka

  • Study site

    Chiyoda-ku, Tokyo

  • Study site

    Edogawa City, Tokyo

  • Study site

    Fujisawa-shi, Kanagawa

  • Study site

    Fukui-shi, Fukui

  • Study site

    Fukuoka, Fukuoka

  • Study site

    Fukuyama-shi, Hiroshima

  • Study site

    Hakodate-shi, Hokkaido

  • Study site

    Hamamatsu, Shizuoka

  • Study site

    Hatsukaichi-shi, Hiroshima

  • Study site

    Himeji-shi, Hyōgo

  • Study site

    Hirosaki-shi, Aomori

  • Study site

    Hiroshima, Hiroshima

  • Study site

    Itami-shi, Hyōgo

  • Study site

    Kagoshima, Kagoshima-ken

  • Study site

    Kamakura-shi, Kanagawa

  • Study site

    Kasugai-shi, Aichi-ken

  • Study site

    Kawasaki-shi, Kanagawa

  • Study site

    Kitakyushu-shi, Fukuoka

  • Study site

    Kobe, Hyōgo

  • Study site

    Kochi, Kochi

  • Study site

    Kofu, Yamanashi

  • Study site

    Komatsu-shi, Ishikawa-ken

  • Study site

    Kumamoto, Kumamoto

  • Study site

    Kurume-shi, Fukuoka

  • Study site

    Kyoto, Kyoto

  • Study site

    Marukame-shi, Kagawa-ken

  • Study site

    Matsuyama, Ehime

  • Study site

    Minato-ku, Tokyo

  • Study site

    Moriguchi-shi, Osaka

  • Study site

    Nagasaki, Nagasaki

  • Study site

    Nagoya, Aichi-ken

  • Study site

    Nishinomiya-shi, Hyōgo

  • Study site

    Ōita, Ohita

  • Study site

    Okayama, Okayama-ken

  • Study site

    Osaka, Osaka

  • Study site

    Ōtsu, Shiga

  • Study site

    Saga, Saga-ken

  • Study site

    Sagamihara-shi, Kanagawa

  • Study site

    Sakai-shi, Osaka

  • Study site

    Sakura-shi, Chiba

  • Study site

    Sapporo, Hokkaido

  • Study site

    Sendai, Miyagi

  • Study site

    Shimotsuke-shi, Tochigi

  • Study site

    Shinagawa-ku, Tokyo

  • Study site

    Shinjuku-ku, Tokyo

  • Study site

    Shunan-shi, Yamaguchi

  • Study site

    Suita-shi, Osaka

  • Study site

    Takamatsu, Kagawa-ken

  • Study site

    Tokorozawa-shi, Saitama

  • Study site

    Tomakomai-shi, Hokkaido

  • Study site

    Toyota-shi, Aichi-ken

  • Study site

    Wakayama, Wakayama

  • Study site

    Yokohama, Kanagawa

Other trials in Japan

About this study

Official title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Ulcerative Colitis

The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).

Read the detailed description

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.

Being tested
Vedolizumab, Vedolizumab placebo
Keywords
Drug therapy
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VedolizumabDrug

    Also called MLN0002

    Vedolizumab intravenous infusion

  • Vedolizumab placeboDrug

    Vedolizumab placebo

Study groups in NCT02039505
Study groupRoleWhat they receive
Induction Phase: Cohort 1, PlaceboPlacebo comparatorVedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
Receives: Drug: Vedolizumab placebo
Induction Phase: Cohort 1, Vedolizumab 300 mgExperimentalVedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
Receives: Drug: Vedolizumab
Induction Phase: Cohort 2, Vedolizumab 300 mgExperimentalVedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
Receives: Drug: Vedolizumab
Maintenance Phase: PlaceboExperimentalVedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
Receives: Drug: Vedolizumab; Drug: Vedolizumab placebo
Maintenance Phase: Vedolizumab 300 mgExperimentalVedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
Receives: Drug: Vedolizumab
Maintenance Phase: Placebo continuationPlacebo comparatorVedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
Receives: Drug: Vedolizumab placebo
Open-Label Cohort: Vedolizumab 300 mgExperimentalVedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
Receives: Drug: Vedolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With a Clinical Response at Week 10 in Induction Phase

    Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores (rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment), a global assessment by the physician, and an endoscopic subscore. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Week 10

  2. Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore >1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Week 60

  3. Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Measured: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  4. Number of Participants With TEAE Related to Body Weight

    Measured: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  5. Number of Participants With TEAE Related to Vital Signs

    Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

    Measured: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  6. Number of Participants With TEAE Related to Electrocardiogram (ECG)

    Measured: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  7. Number of Participants With Markedly Abnormal Laboratory Parameters Values

    The laboratory values outside the range (Hemoglobin <=7 g/dL, Lymphocytes <500 /µL, WBC <2000 /µL, Platelets <7.5 10^4/µL, Neutrophils <1000 /µL, alanine aminotransferase (ALT) >3.0 U/L x upper limit of normal (ULN), aspartate aminotransferase (AST) >3.0 U/L x ULN, Total Bilirubin >2.0 mg/dL x ULN, Amylase >2.0 (U/L) x ULN were considered markedly abnormal. Only laboratory parameters with events were represented.

    Measured: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Secondary outcomes (12)

  1. Percentage of Participants With Clinical Remission at Week 10 in Induction Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore >1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Week 10

  2. Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

    Measured: Week 10

  3. Percentage of Participants With Durable Clinical Response in Maintenance Phase

    Durable clinical response is defined as reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Weeks 10 and 60

  4. Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase

    Mucosal healing is defined as a Mayo endoscopic subscore of ≤1 point. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern, mild friability); 2=Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration).

    Measured: Week 60

  5. Percentage of Participants With Durable Remission in Maintenance Phase

    Durable clinical remission is defined as complete Mayo score of ≤2 points and no individual subscore >1 point at both Weeks 10 and 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Weeks 10 and 60

  6. Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase

    Clinical Remission is defined as a complete Mayo score of ≤2 points and no individual subscore >1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 60. Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Measured: Week 60

  7. Serum Vedolizumab Concentration in Induction Phase

    Measured: Pre-dose at Weeks 2, 6, 10 and 14

  8. Serum Vedolizumab Concentration in Maintenance Phase

    Measured: Pre-dose at Weeks 2, 6, 10, 14, 22, 30 and 60

  9. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of electrochemoluminescent (ECL) assay.

    Measured: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  10. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Blood samples were collected and tested for serum concentration of anti-vedolizumab antibodies in a laboratory by means of ECL assay.

    Measured: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  11. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

    Measured: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  12. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Blood samples were collected, and serum neutralizing AVA was determined only for the AVA-positive samples in a laboratory by means of ECL assay.

    Measured: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2014 (estimated)
  2. Study start4 Feb 2014
  3. Primary completion27 Feb 2018
  4. Study completion28 Jun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
292 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02039505
Sponsor's protocol ID
MLN0002/CCT-101
Other IDs
U1111-1151-6762, JapicCTI-142403
Status last verified
Apr 2019
First submitted
16 Jan 2014
Last updated
25 Apr 2019
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Publications

  • Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol. 2022 Jan;37(1):81-88. doi: 10.1111/jgh.15667. Epub 2021 Sep 7.

    PubMed 34409654

  • Nagahori M, Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Pinton P, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Hibi T, Watanabe M. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFalpha-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion. 2021;102(5):742-752. doi: 10.1159/000512235. Epub 2021 Jan 15.

    PubMed 33454706

  • Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10.

    PubMed 32635680

  • Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019 Feb 26;14(2):e0212989. doi: 10.1371/journal.pone.0212989. eCollection 2019.

    PubMed 30807613

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Vedolizumab in people with Ulcerative Colitis, run by Takeda at 59 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 44 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 59 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Mar 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With a Clinical Response at Week 10 in Induction Phase (time frame: Week 10). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02039505, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT02039505 | AzTrials